R-sibutramine metabolite - Sepracor
Alternative Names: (+)-Desmethylsibutramine - Sepracor; (+)-Didesmethylsibutramine - Sepracor; R-DDMS; R-Desmethylsibutramine - Sepracor; R-Didesmethylsibutramine - SepracorLatest Information Update: 27 Jun 2006
At a glance
- Originator Sepracor
- Class
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder; Erectile dysfunction; Major depressive disorder; Stress incontinence
Most Recent Events
- 27 Jun 2006 No development reported - Phase-I for Attention-deficit hyperactivity disorder in USA (PO)
- 27 Jun 2006 No development reported - Phase-I for Stress incontinence in USA (unspecified route)
- 27 Jun 2006 No development reported - Phase-II for Depression in USA (PO)